nc886 or VRNA2-1 has recently been identified as a
noncoding RNA instead of a vault
RNA or a pre-
microRNA. Several studies have reported that pre-miR-886 plays a
tumor-suppressive role in a wide range of
cancer cells through its activity as a cellular
protein kinase RNA-activated (PKR)
ligand and repressor. However, by sequencing stem-PCR products, we found that a
microRNA originating from this precursor, vault RNA2-1-5p (VTRNA2-1-5p), occurs in
cervical cancer cells. The expression levels of the predicted targets of VTRNA2-1-5p are negatively correlated with VTRNA2-1-5p levels by quantitative reversion transcription PCR (qRT-PCR). Previous results have shown that VTRNA2-1-5p is overexpressed in human cervical
squamous cell carcinomas (CSCCs) compared with adjacent healthy tissues. Inhibition of VTRNA2-1-5p increases
Bax protein expression and apoptotic cell death in
cervical cancer cells. Our findings suggest that VTRNA2-1-5p has oncogenic activity related to the progression of
cervical cancer. Here, we report that VTRNA2-1-5p directly targeted p53 expression and functioned as an oncomir in
cervical cancer. VTRNA2-1-5p inhibition decreased
cervical cancer cell invasion, proliferation, and tumorigenicity while increasing apoptosis and p53 expression. Interestingly, VTRNA2-1-5p inhibition also increased
cisplatin-induced apoptosis of HeLa and SiHa cells. In human clinical
cervical cancer specimens, low p53 expression and high VTRNA2-1-5p expression were positively associated.In addition, VTRNA2-1-5p was found to directly target the 5' and
3' untranslated regions (
UTRs) of p53. We propose that VTRNA2-1-5p is a direct regulator of p53 and suggest that it plays an essential role in the apoptosis and proliferation of
cervical cancer cells.